Ryzumvi

Generic name: Phentolamine Ophthalmic Solution
Dosage form: eye drop (0.75%)
Drug class: Miscellaneous ophthalmic agents

Usage of Ryzumvi

Ryzumvi (phentolamine) is an eye drop used for pharmacologically-induced mydriasis, or more simply, it is used to reverse dilated pupils caused by eye drops used during eye examinations for routine eye check-ups, disease monitoring, or surgical procedures.

Dilated pupils cause sensitivity to light (photophobia) and blurred vision, which may make it difficult to read, work, and drive, which can last 24 hours after the examination. Ryzumvi eye drops are used to speed up the return to normal pupil size, to restore normal vision, and reduce light sensitivity so there is less disruption to daily activities.

Ryzumvi (phentolamine ophthalmic solution) became a FDA-approved medicine on September 27, 2023, to treat pharmacologically-induced mydriasis - dilation of the pupil of the eye caused by eye drops. Approval was supported by positive results in the MIRA-2 and MIRA-3 clinical trials.

During the development of phentolamine ophthalmic solution, it was given the brand name Nyxol which was later changed to Ryzumi.

Ryzumvi side effects

Common Ryzumvi side effects include:

eye discomfort including pain, stinging, and burning (16%)

red eyes (12%).

Non-eye related side effect include:

A distorted or horrible taste in your mouth - dysgeusia (6%).

Before taking Ryzumvi

Pregnancy

Tell your healthcare provider if you are pregnant or plan to become pregnant, as there is no available data with Ryzumvi administration in pregnant women. Ryzumvi should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

Tell your healthcare provider if you are breastfeeding or planning to breastfeed, as there is no information regarding the presence of Ryzumvi in human milk, the effects on breastfed infants, or the effects on milk production.

Relate drugs

How to use Ryzumvi

Adults and pediatric patients aged 12 years or older: Instill 1 or 2 drops in each dilated eye following the completion of the ophthalmic examination or procedure. If 2 drops are instilled, the second drop should be administered 5 minutes after the first drop.

Pediatric patients aged 3 to 11 years: Instill 1 drop in each dilated eye following the completion of the ophthalmic examination or procedure.

Comment: One single-patient-use vial can be used to dose each dilated eye. Discard the single-patient-use vial immediately after use. Contact lens wearers should be advised to remove their lenses prior to the instillation of Ryzumvi and wait 10 minutes after dosing before reinserting their contact lenses.

Dosage Form

Ryzumvi (phentolamine ophthalmic solution) is available in 0.75% single-patient-use vial with a 0.31 mL fill.

One strip of 5 single-patient-use vials is packaged into a foil pouch, with 6 foil pouches in a carton.

One single-patient-use vial should be dispensed for each patient, and it can be used to dose both eyes.

Warnings

Ryzumvi should not be used in patients who have active ocular inflammation (uveitis).

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.